Back to search

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

Davi D M Ross, Andrew Grigg, Anthony P. Schwarer, Christopher Arthur, Kerryn Loftus
DOI: 10.1182/blood.v112.11.1102.1102
Blood

Data up to Jan 2025

Published2008
Citations22
References0
Fields
MedicineInternal medicineOncologyGastroenterology

Total Citations Per Year

Abstract

References (0)

No references found

Cited By (0)

Loading...
The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a… (2008) – Blood | Metascience Observatory Explorer